{"id":654915,"date":"2026-06-24T00:20:22","date_gmt":"2026-06-24T00:20:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/654915\/"},"modified":"2026-06-24T00:20:22","modified_gmt":"2026-06-24T00:20:22","slug":"definium-lsd-therapy-for-major-depression-helped-patients-in-phase-3-trial","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/654915\/","title":{"rendered":"Definium LSD therapy for major depression helped patients in Phase 3 trial"},"content":{"rendered":"

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n

Definium Therapeutics said Monday that its LSD therapy significantly helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.<\/p>\n

Six weeks after a single dose, patients on the pill, called DT120, experienced a 13.3-point drop on a depression test called the Montgomery-\u00c5sberg Depression Rating Scale (MADRS), compared with a 5.2-point drop among patients taking placebo.<\/p>\n

By 12 weeks, the effect waned a bit but was largely maintained, as patients on the pill had an 11-point drop from their baseline, compared with a 3.6-point drop in the placebo group.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…\n","protected":false},"author":2,"featured_media":654916,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[3252,33453,5237,102,1906,6623,13214,7555,57202,56,54,55],"class_list":["post-654915","post","type-post","status-publish","format-standard","has-post-thumbnail","category-mental-health","tag-biotechnology","tag-clinical-trials","tag-drug-development","tag-health","tag-mental-health","tag-mentalhealth","tag-pharmaceuticals","tag-psychedelics","tag-stat","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/654915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=654915"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/654915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/654916"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=654915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=654915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=654915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}